Guardant Health has entered a strategic, multi-year agreement with Merck to leverage the Guardant Infinity Smart platform in support of Merck’s global oncology pipeline. Under the pact, Guardant’s liquid and tissue biopsy assays will serve as clinical trial enrolling tools across Phase II and III studies spanning North America, Europe and Asia-Pacific. Both companies will jointly evaluate the development of novel therapies using Guardant’s liquid biopsy tests as companion diagnostics, then partner on global commercialization efforts in the U.S., U.K., EU and Asia-Pacific markets. This collaboration aims to accelerate patient enrollment, enhance molecular stratification and shorten timelines for pivotal cancer therapy approvals.

The Guardant Infinity Smart platform integrates next-generation sequencing of circulating tumor DNA with AI-driven analytics to profile over 500 cancer-related genes from a single blood draw. Guardant Health reports the platform has already supported enrollment for more than 20 pivotal studies in lung, breast and colorectal cancers, with median turnaround times under seven days. Co-CEO Helmy Eltoukhy emphasized that the platform’s deep molecular insights will ensure each trial identifies the patients most likely to benefit, driving trial success rates and reducing development costs by an estimated 15–20%.

Guardant Health’s Shield blood-based colorectal cancer screening test saw screening volumes jump 335% year-over-year following its rollout with Quest Diagnostics. Through the collaboration, Shield now reaches 650,000 physician offices and 50 million Americans at average risk, removing barriers posed by traditional stool-based tests. Early data indicate a 92% compliance rate on first-time orders and a 20% increase in adenoma detection compared to standard screening methods, underscoring Shield’s potential to drive meaningful improvements in early cancer detection and long-term patient outcomes.

Guardant Health expects full-year 2025 revenue to reach $981 million, a 33% increase over the prior year, driven by strong uptake of both the Infinity Smart platform and Shield screening test. Preliminary fourth quarter revenue of $280 million reflects a 39% year-over-year rise, outpacing the broader precision oncology peer group. With operating margins improving by 250 basis points sequentially and operating cash flow turning positive in Q3 2025, the company is poised to reinvest in R&D and commercial expansion, targeting double-digit revenue growth and potential profitability by mid-2026.